Tag: Bcl 2 inhibitor

Overexpression of anti-apoptotic Bcl-2 family proteins is a hallmark of many cancers, making them an attractive target for novel therapies. The investigational anti-cancer agent Obatoclax is a BH3 mimetic designed to inhibit these pro-survival proteins. So, what is the mechanism of action of Obatoclax? Its effects are multifaceted and extend beyond simple apoptosis inhibition.

In studies of patients with Chronic Lymphocytic Leukemia (CLL), the rate of Tumor Lysis Syndrome (TLS), a serious complication, was 2% when following the proper initial treatment plan for venetoclax. Understanding **how do you take venetoclax** correctly is critical for safety and efficacy.

In a phase I clinical trial for extensive-stage small cell lung cancer (ES-SCLC), 96% of patients treated with a combination including Obatoclax experienced neutropenia [1.2.1]. This article explores the full spectrum of what are the side effects of the drug Obatoclax.

As a potent and selective BCL-2 inhibitor, venetoclax represents a major advance in targeted cancer therapy, offering new treatment options for patients with specific blood cancers. In this comprehensive overview, we explore **what is venetoclax**, its mechanism, clinical applications, and key considerations for patients and healthcare providers.